These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 26369911)

  • 21. [Off-label use of intravenous immunoglobulin g in a highly complex pediatric hospital in Argentina. A prospective observational study].
    Rivero R; Strusberg I; Joekes S; Yori S; Barros Herrero C; Rousseau MN; Fontana D
    Rev Fac Cien Med Univ Nac Cordoba; 2024 Jun; 81(2):254-269. PubMed ID: 38941229
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recommended indications for the administration of polyclonal immunoglobulin preparations.
    Delforge M; Farber CM; Spath P; Kaveri S; Witte T; Misbah SA; Hübner R; Haerynck F; Latinne D; Muylle L; Toungouz M; Deneys V;
    Acta Clin Belg; 2011; 66(5):346-60. PubMed ID: 22145269
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent trends in practice patterns and comparisons between immunoglobulin and corticosteroid in pediatric immune thrombocytopenia.
    Okubo Y; Michihata N; Morisaki N; Hangai M; Matsui H; Fushimi K; Yasunaga H
    Int J Hematol; 2018 Jan; 107(1):75-82. PubMed ID: 28849369
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pneumococcal antibody levels in children with PID receiving immunoglobulin.
    Tuerlinckx D; Florkin B; Ferster A; De Schutter I; Chantrain C; Haerynck F; Philippet P; Strengers P; Laub R
    Pediatrics; 2014 Jan; 133(1):e154-62. PubMed ID: 24366995
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The case for a national service for primary immune deficiency disorders in New Zealand.
    Ameratunga R; Steele R; Jordan A; Preece K; Barker R; Brewerton M; Lindsay K; Sinclair J; Storey P; Woon ST
    N Z Med J; 2016 Jun; 129(1436):75-90. PubMed ID: 27355232
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prescribing for off-label use and unauthorized medicines in three paediatric wards in Finland, the status before and after the European Union Paediatric Regulation.
    Lindell-Osuagwu L; Hakkarainen M; Sepponen K; Vainio K; Naaranlahti T; Kokki H
    J Clin Pharm Ther; 2014 Apr; 39(2):144-53. PubMed ID: 24329556
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A cost-benefit analysis of intravenous immunoglobulin treatment in children with Kawasaki disease.
    Arj-ong S; Chotivitayatarakorn P; Lertsapcharoen P; Khongphatthanayothin A; Thisyakorn C
    J Med Assoc Thai; 2003 Jun; 86 Suppl 2():S179-88. PubMed ID: 12929987
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative net cost impact of the utilization of romiplostim and intravenous immunoglobulin for the treatment of patients with immune thrombocytopenia in Québec, Canada.
    Pettigrew M; Garces K; Deuson R; Kassis J; Laroche V
    J Med Econ; 2013; 16(2):318-26. PubMed ID: 23216012
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intravenous immunoglobulin: a biological corticosteroid-sparing agent in some autoimmune conditions.
    Watad A; Amital H; Shoenfeld Y
    Lupus; 2017 Sep; 26(10):1015-1022. PubMed ID: 28420062
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimization of intravenous immune globulin use at a comprehensive cancer center.
    Figgins BS; Aitken SL; Whited LK
    Am J Health Syst Pharm; 2019 Nov; 76(Supplement_4):S102-S106. PubMed ID: 31621877
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study].
    Qin LJ; Wang HW; Hu XF; Liu QJ; Shi H; Wei YX; Chen QJ; Cheng PX
    Zhonghua Er Ke Za Zhi; 2006 Dec; 44(12):891-5. PubMed ID: 17254453
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravenous immunoglobulin preparation type: association with outcomes for patients with acute Kawasaki disease.
    Manlhiot C; Yeung RS; Chahal N; McCrindle BW
    Pediatr Allergy Immunol; 2010 May; 21(3):515-21. PubMed ID: 20546528
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic profile of orphan medicines.
    de Barros CM; Papoila AL
    Pharmacoepidemiol Drug Saf; 2007 Apr; 16(4):435-40. PubMed ID: 16958155
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease.
    Sakata K; Hamaoka K; Ozawa S; Niboshi A; Yoshihara T; Nishiki T; Nakagawa Y; Kazuta K; Morimoto Y; Kamiya Y; Yamamoto T; Horii Y; Kido S
    Eur J Pediatr; 2007 Jun; 166(6):565-71. PubMed ID: 17103193
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intravenous immunoglobulin utilization in the Canadian Atlantic provinces: a report of the Atlantic Collaborative Intravenous Immune Globulin Utilization Working Group.
    Constantine MM; Thomas W; Whitman L; Kahwash E; Dolan S; Smith S; Caudle CJ; Burton E; Anderson DR;
    Transfusion; 2007 Nov; 47(11):2072-80. PubMed ID: 17958537
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ImmunoglobuliN in the Treatment of Encephalitis (IgNiTE): protocol for a multicentre randomised controlled trial.
    Iro MA; Sadarangani M; Absoud M; Chong WK; Clark CA; Easton A; Gray V; Kneen R; Lim M; Pike M; Solomon T; Vincent A; Willis L; Yu LM; Pollard AJ
    BMJ Open; 2016 Nov; 6(11):e012356. PubMed ID: 27810972
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of high-dose intravenous immunoglobulin in systemic autoimmune diseases.
    Tufan F; Kamali S; Erer B; Gul A; Inanc M; Ocal L; Konice M; Aral O
    Clin Rheumatol; 2007 Nov; 26(11):1913-5. PubMed ID: 17636363
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early intravenous immunoglobulin replacement in hypogammaglobulinemic heart transplant recipients: results of a clinical trial.
    Sarmiento E; Diez P; Arraya M; Jaramillo M; Calahorra L; Fernandez-Yañez J; Palomo J; Sousa I; Hortal J; Barrio J; Alonso R; Muñoz P; Navarro J; Vicario J; Fernandez-Cruz E; Carbone J
    Transpl Infect Dis; 2016 Dec; 18(6):832-843. PubMed ID: 27639067
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of intravenous immunoglobulin in toxic epidermal necrolysis: a retrospective analysis of 64 patients managed in a specialized centre.
    Lee HY; Lim YL; Thirumoorthy T; Pang SM
    Br J Dermatol; 2013 Dec; 169(6):1304-9. PubMed ID: 24007192
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic yield and cost-effectiveness of investigations in patients presenting with isolated lower motor neuron signs.
    Alanazy MH; White C; Korngut L
    Amyotroph Lateral Scler Frontotemporal Degener; 2014 Sep; 15(5-6):414-9. PubMed ID: 24863134
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.